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Summary 
T lymphocytes recognize antigens consisting ofpeptides presented by class I and II major histo- 
compatibility complex (MHC) molecules. The peptides identified so far have been predictable 
from the amino acid sequences of proteins. We have identified the natural peptide target of a 
CTL clone that recognizes the tyrosinase gene product on melanoma cells. The peptide results 
from posttranslational conversion ofasparagine to aspartic  acid. This change is of central impor- 
tance for peptide recognition by melanoma-specific T cells, but has no impact on peptide bind- 
ing to the MHC molecule. This posttranslational modification has not been previously described 
for any MHC-associated peptide  and  represents  the  first  demonstration  of posttranslational 
modification of a naturally processed class I-associated peptide. This observation is relevant to 
the identification and prediction of potential peptide antigens. The most likely mechanism for 
production of this peptide leads  to the suggestion that antigenic peptides can be derived from 
proteins that are translated into the endoplasmic reticulum. 
C 
lass  I  molecules  of MHC  bind  to  peptides  derived 
from  intracellular  pathogens  or  from  proteins  ex- 
pressed in tumor cells, and present them on the cell surface 
to the host immune system (1-3). Identification of the spe- 
cific peptides that constitute T  cell epitopes has been diffi- 
cult without prior knowledge of the source protein. How- 
ever, peptides recognized by human melanoma--specific T 
cells have recently been identified from five proteins using 
two alternative strategies.  One approach has been to gener- 
ate genomic or cDNA libraries from tumor cells followed 
by transfection of  progressively smaller subsets of these mo- 
lecular clones into cells that express the appropriate MHC 
molecule, but not the tumor-specific epitope (4--14). Mo- 
lecular clones that encode T  cell epitopes are identified by 
their ability to reconstitute tumor-specific T  cell recogni- 
tion  of the  transfected cells.  The  exact T  cell epitope is 
then identified by a combination of molecular subcloning 
The contributions  of  the first two authors were equivalent  and their order 
should be considered  arbitrary. 
and the  use  of synthetic peptides based  on  the predicted 
amino acid sequence. This approach led to the identifica- 
tion of antigens encoded by genes whose expression is spe- 
cific for tumors, such as MAGE and of other antigens re- 
lated  to  melanocyte differentiation such  as  tyrosinase  (4, 
13).  In the second approach, naturally occurring peptides 
associated with MHC molecules on the tumor cells are di- 
rectly extracted, fractionated by HPLC, and used to reconsti- 
tute recognition by melanoma-specific CTL of a nonmela- 
noma  cell  expressing  appropriate  MHC  molecules  (15). 
The peptide epitope within a reconstituting peptide frac- 
tion is identified and sequenced by tandem mass spectrom- 
etry  (16,  17).  Using  this  approach,  a  peptide,  YLEPG- 
PVTA, from the protein Pmel-17/gp100, was identified as 
an  epitope  for  HLA-A2.1-restricted,  melanoma-specific 
CTL from multiple individuals (18). 
A  different  naturally  occurring  HLA-A2.1-associated 
peptide,  YMDGTMSQV,  was  identified  by  mass  spec- 
trometry  because  it  was  very  abundant  in  peptides  ex- 
tracted from melanoma  cells but was  absent in lymphoid 
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anocytic lineage (reported incorrectly in reference 19)  (18). 
The  sequence  of this peptide was  identical to  a  nonamer 
peptide  corresponding  to  residues  368-376  of tyrosinase, 
except that  aspartic  acid  (D)  was  found  instead  of aspar- 
agine (N) at position three. 
It  is  interesting  to  note  that  the  genetic  approach  de- 
scribed above had indicated that this region of the gene en- 
coded an epitope recognized by HLA-A2.1-restricted, ty- 
rosinase-specific CTL (14). Here, we show that the naturally 
occurring tyrosinase peptide recognized by these CTL is in 
fact the species identified by mass spectrometry, and that it 
is derived by the posttranslational modification of a geneti- 
cally encoded asparagine residue to aspartic acid. 
Materials and Methods 
Cell Lines and Peptides.  Melanoma line NA8Mel+tyr was de- 
rived  from  transfection  of  the  tyrosinase  negative  cell  line 
NA8Mel with the tyrosinase cDNA 123.B2  (13). T2 is a mutant 
human B lymphoblastoid cell line (20, 21), which was a kind gift 
from Dr. Peter Cresswell (Yale University, New Haven, CT). All 
cell lines were maintained in RPMI-1640 medium supplemented 
with  10%  FCS  in  a  humidified atmosphere,  with  5%  CO  2 at 
37~  Synthetic peptides were made by standard Fmoc chemistry 
using a  peptide synthesizer (model AMS422;  Gilson Co.  Inc., 
Middleton, WI). All peptides were purified to >98% by reverse- 
phase HPLC  on a  C-4  column  (VYDAC,  Hesperia, CA)  with 
0.05% TFA/water and an acetonitrile gradient. 
CTL Clone IVSB and Cytotoxic Assays.  The  tyrosinase-specific 
CTL  clone  IVSB  was produced by limiting dilution from  re- 
sponders  of autologous mixed lymphocyte tumor  cell cultures 
and maintained in long-term culture as described previously (13, 
14).  Standard SlCr release assays were performed to  determine 
CTL recognition of tyrosinase peptides. Indicated concentrations 
of synthetic tyrosinase peptides were  incubated with  2  ￿  10  3 
SlCr-labeled HLA-A2.1 + T2  target cells for  1 h  at 37~  CTL 
were added at an E/T ratio of 20:1  and chromium release was 
measured after a 4-h incubation of 37~  SlCr-labeled T2 target 
cells were also incubated with 20 ILl of culture supematant con- 
taining anti-HLA-A2 mAb MA2.1  (22) for 1 h before incubation 
with indicated concentrations of synthetic peptides. 
Class I Binding  Assay.  The  ability of the  tyrosinase peptides 
to compete with the radiolabeled standard peptide FLPSDYFPSV 
for binding to purified HLA-A2.1 molecules was measured with 
an equilibrium binding assay as described (23, 24).  Indicated con- 
centrations of tyrosinase peptides were incubated with iodinated 
hepatitis B virus core peptide FLPSDYFPSV (5-10 nM, specific 
activity 5-10 ￿  1017 cpm/mol), purified class I molecules (10-50 
nM)  (23),  and  1  ~M  human  132-microglobulin (Calbiochem- 
Novabiochem Corp., La Jolla, CA) at room temperature in PBS, 
pH 7.0, 0.05%  NP-40, 1 mM PMSF, 1.3 mM 1,10-phenanthro- 
line, 73 txM pepstatin A, 8 mM EDTA, and 200  IxM tosyllysyl- 
chloromethyl ketone  (TLCK). After 48 h,  class I-peptide com- 
plexes and free peptides were separated by gel filtration using a 
Sephadex G-50 column (2-ml bed volume) eluted with PBS, pH 
7.0, 0.5% NP40, and 0.1% NaN 3. Class I bound and free radioac- 
tivity were  measured and peptide concentrations inducing 50% 
inhibition of binding of the standard peptide (ICs0) determined. 
Peptides were tested in three independent experiments. 
HLA-A2.1-associated  Peptide Isolation and Microcapillary Reverse- 
Phase HPLC Coelution.  Peptides were acid eluted from amnity- 
purified HLA-A2.1 molecules as described (15,  19). Briefly, cells 
were washed three times in cold PBS and detergent solubilized in 
1% CHAPS,  174  Ixg/ml PMSF,  5 mg/ml aprotinin,  10 mg/ml 
leupeptin, 16 mg/ml pepstatin A, 33 mg/ml iodoacetamide, 0.2% 
sodium azide, and 0.03 mg/ml EDTA for 1 h at 4~  After cen- 
trifugation at  100,000  g for 1 h  at 4~  the supematant was fil- 
tered (0.22  p,m) and passed over a protein A-Sepharose column 
containing the mAb BB7.2. HLA-A2.1 molecules and associated 
peptides were eluted with 0.2 N  acetic acid, pH 2.7, and peptides 
were dissociated at pH 2.1 by bringing the solution to 10% acetic 
acid followed by boiling for 5 rain. Finally, peptides were centri- 
fuged  through  Ultrafree-CL  5000-kD  filters  (Millipore Corp., 
Bedford, MA) at 2,500 g for 5 h. Filtrates were concentrated us- 
ing vacuum centrifugation and stored at -80~ 
HLA-A2.1-associated peptides were also isolated from T2 cells 
pulsed with synthetic peptides. T2  cells (10  ')) were preincubated 
with 0.5 mM synthetic peptide for 12 h  at 37~  before immu- 
noaffinity purification of HLA-A2.1  molecules and acid elution 
ofpeptides as described above. Isolated peptides were loaded onto 
a C18 microcapillary column (75 Ixm i.d. ￿  12 cm) and gradient 
eluted using acetonitrile and 0. t M acetic acid with the concentra- 
tion of acetonitrile increasing at 2%/rain into a triple quadrupole 
mass spectrometer (model MAT TSQ-7000;  Finnigan, San Jose, 
CA) equipped with an electrospray ion source. Scans were acquired 
every 1.5  s over a mass range m/z 300-1,400  and then plotted 
with intensities for mass-to-charge ratio (m/z) 1,031  to 1,032. 
Mass Spectrometric Peptide Sequencing.  Collision  activated  dis- 
sociation (CAD)  1 mass spectra were recorded on peptide methyl 
esters (16,  19). Since the amino acids at position 3 in the two ty- 
rosinase peptides YMNGTMSQV and YMDGTMSQV differ by 
a single mass unit, confirmation of the sequences was obtained by 
recording CAD  spectra on  the  corresponding methyl  esters,  as 
this derivatization results in a 14 mass unit shift for each carboxy- 
late group, including the COOH terminus. 
Results 
The  naturally  occurring  peptide  YMDGTMSQV  was 
tested for recognition by the tyrosinase-specific CTL clone 
IVSB, which had been used to identify the genetically en- 
coded  peptide  YMNGTMSQV  (14).  It  is  interesting  to 
note that YMDGTMSQV  sensitized target cells for lysis at 
a  100-fold lower concentration than did YMNGTMSQV 
(half-maximal lysis with 0.1  and 10 mM, respectively) (Fig. 
1 A). Even when target cells were pretreated with the mAb 
MA2.1  to  facilitate exogenous  peptide binding to  HLA- 
A2.1  (14,  22),  the  concentration  of YMNGTMSQV  re- 
quired to  give half-maximal target  cell lysis was  >1  IxM. 
This is significantly higher than that observed for numerous 
other peptide epitopes (17,  18, 25-28). 
To determine whether differences in target cell sensitiz- 
ing activity were due to differences in the ability of the in- 
dividual  peptides  to  bind  to  HLA-A2.1  molecules,  the 
binding affinity of the two peptides was measured using a 
Abbreviations used in this paper: CAD, collision-activated  dissociation;  Elk, 
endoptasrnic reticulum; PNGase, peptide:N-glycanase; TAP, transporter 
associated  with antigen processing. 
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Figure 1.  (A) Recognition oftyrosinase peptides by melanoma-specific 
CTL IVSB. Indicated concentrations of synthetic tyrosinase peptides were 
incubated with 2  ￿  103 51Cr-labeled HLA-A2.1 § T2 target cells for 1 h at 
37~  T2 is a mutant human B  lymphoblastoid cell line  (20, 21).  IVSB 
CTL were added at an E/T ratio of 20 : 1 and chromium release was mea- 
sured after a 4-h incubation at 37~  SlCr-labeled T2 target cells were also 
incubated with anti-HLA-A2 mAb MA2.1 for 1 h before incubation with 
indicated  concentrations  of synthetic  peptides.  Targets  were  T2  cells 
pulsed with YMNGTMSQV  (O) and YMDGTMSQV  ([]),  or MA2.1- 
treated T2 cells  pulsed with YMNGTMSQV  (0)  and YMDGTMSQV 
(').  (B) Binding of synthetic tyrosinase peptides to HLA-A2.1. The abil- 
ity of the tyrosinase peptides to  compete with the radiolabeled standard 
peptide FLPSDYFPSV for binding to purified HLA-A2.1 molecules was 
measured with an equilibrium binding assay as described  (23,  24).  (I) 
YMDGTMSQV;  (V]) YMNGTMSQV;  (0) ALWGFFPVL, another en- 
dogenous peptide isolated from HLA-A2.1  (17);  (O) API~TVALTA, an 
endogenous peptide isolated from HLA-B7 that does not bind to HLA- 
A2.1 (48). 
for this species.  One possible  explanation of these observa- 
tions is that this aspartic acid-containing peptide is derived 
from a previously undescribed allelic variant of tyrosinase 
or a mutated tyrosinase gene. Although asparagine has been 
found at this position (residue 371 of the precursor protein) 
in published sequences of human tyrosinase (13, 29, 30), an 
allelic form containing a threonine substitution at this posi- 
tion has been  reported in oculocutaneous albino patients 
(31). The naturally processed peptide YMDGTMSQV was 
identified in HLA-A2.1-associated peptides extracted from 
two melanoma cell  lines,  DM6  and DM93  (our unpub- 
lished data) and the tyrosinase genes in these cell lines have 
not been sequenced. Another possibility is that this peptide 
originates from a gene distinct from tyrosinase. Finally, the 
naturally processed peptide could arise from the genetically 
encoded tyrosinase sequence through posttranslational  modi- 
fication. 
To distinguish among these hypotheses, mass spectrometry 
was used to analyze the HLA-A2.1-associated peptides ex- 
tracted from the melanoma cell line NA8Mel and NA8Mel+ 
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quantitative binding assay (23, 24).  Inhibition of the bind- 
ing of a standard peptide to purified HLA-A2,1 molecules 
was observed at similar concentrations of YMDGTMSQV 
and YMNGTMSQV  (Fig.  1 B). Thus, the asparagine  and 
aspartic  acid  residues  at  position  three  of these  peptides 
have either a similar or no influence on peptide binding to 
HLA-A2.1; differences in binding affinity do not account 
for the difference in peptide recognition by the CTL. 
Preferential CTL recognition of the naturally processed 
YMDGTMSQV suggests  that the TCR expressed by the 
tyrosinase-specific CTL clone  IVSB  has  a  greater affinity 
Figure 2.  Ion chromatograms recorded on HLA-A2.1-associated pep- 
tides from NA8Mel and NA8MeI+ tyr transfectant. Isolated peptides were 
loaded onto a C18 microcapillary column (75 ~m i.d.  ￿  12 cm) and gra- 
dient  eluted  into  a  Finnigan-MAT TSQ-7000  triple  quadrupole  mass 
spectrometer equipped with an electrospray ion source. Scans were  ac- 
quired  every  1.5 s over a  mass range m/z 300-1,400  and then plotted 
with intensities for m/z 103 i- 1032 (A) Ion chromatogram for m/z 1031- 
1032 from NA8Mel material equivalent to 1.3 ￿  108 cells.  (B) Ion chro- 
matogram for m/z  1,031-1,032  from NA8Mel+tyr material equivalent 
to  4  X  10  v  cells.  (C)  Ion  chromatogram  for  m/z  1,031-1,032  from 
NA8Mel+tyr  material  equivalent  to  4  X  107  cells  with  synthetic 
YMNGTMSQV peptide added.  (D)  Ion chromatogram for m/z 1,031- 
1,032 from NA8Mel+tyr material equivalent to 4  X  107 cells with syn- 
thetic YMDGTMSQV peptide added. 
529  Skipper  et al. tyr.  NA8mel  does  not  express  a  tyrosinase  gene,  whereas 
NA8Mel+tyr  was  transfected  with  a  tyrosinase  gene  en- 
coding asparagine at position 371  (13).  PCR. amplification 
and sequencing of tyrosinase RNA  from this cell line con- 
firmed that no mutation had occurred in this sequence after 
transfection  (data  not  shown).  Peptides  YMDGTMSQV 
and YMNGTMSQV  have molecular masses  of 1,032 and 
1,031 daltons, respectively. Analysis of the mixture of natu- 
rally processed peptides extracted from NA8Mel by micro- 
capillary reversed-phase  HPLC failed to detect any species 
of mass  1,031-1,032  at  >0.17  fmol/3  ￿  107  cells  (Fig.  2 
A).  However,  a single major peak,  corresponding to pep- 
tide(s) in the mass window 1031-1032, was detected at the 
level  of 200  fmol/3  ￿  10  v cells  among the  peptides  ex- 
tracted from NASMel+tyr (Fig. 2/3).  This result confirms 
that an HLA-A2.1-associated peptide  of this mass was de- 
rived  from  the  tyrosinase  gene  product.  When  synthetic 
YMNGTMSQV  was  added  to  the  peptide  extract,  two 
distinct peaks were detected in this mass range  (Fig.  2  C), 
indicating that the naturally processed peptide did not have 
this  sequence.  Furthermore,  no  signal  above  background 
was discernible  at the elution position of YMNGTMSQV 
in normal extracts  of NA8Mel+tyr  (Fig.  2  B and our un- 
published  data),  indicating  that  this  tyrosinase  gene  en- 
coded peptide is not present among HLA-A2.1-associated 
peptides.  By  contrast,  the  synthetic  peptide  YML)GTM- 
SQV  did  coelute  with  the  naturally  occurring  tyrosinase 
peptide  from  NA8Mel+tyr  (Fig.  2  D),  suggesting  that 
these peptides were identical.  Proof for this conclusion was 
provided by obtaining sequence  information  on the  natu- 
rally occurring tyrosinase peptide.  CAD mass spectra were 
recorded on (M  +  H) + ions of the corresponding peptide 
methyl esters.  The CAD spectrum representing the peptide 
extracted  from  NA8Mel+tyr  (Fig.  3  A)  was  identical  to 
that  of the  synthetic  tyrosinase  peptide  YMI~GTMSQV 
(Fig. 3  B), and distinct from that of YMNGTMSQV  (Fig. 
3  C). This establishes that the peptide encoded by the tyro- 
sinase gene has been posttranslationally modified before its 
presentation by HLA-A2.1 on the surface of these cells. 
Creation of the naturally occurring peptide YMDGTM- 
SQV from the  genetically encoded sequence  involves de- 
amidation  of asparagine  to  aspartic  acid.  Nonenzymatic 
deamidation  of unmodified  asparagine  residues  has  been 
documented for a variety of proteins and is frequently asso- 
ciated with the presence of an asparagine-glycine sequence 
as occurs at positions 371-372 in tyrosinase (32).  However, 
although the half-lives of deamidation in these proteins and 
peptides depend on both their sequence and structure, they 
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Figure 3.  CAD mass spectra recorded on peptide methyl esters. The 
derivatization of peptides YMNGTMSQV and YMDGTMSQV results 
in a 14 mass unit shift for each carboxylate group, including the COOH 
terminus. CAD mass spectrum of (M+H) + ions at m/z: (A) 1,059 from 
A2.1-associated peptides isolated from NA8Mel  +tyr; (/3) 1,059 from syn- 
thetic YMDGTMSQV; (C) 1,045 from synthetic YMN..N_GTMSQV. 
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Figure 4.  Ion chromatograms  ofpeptides isolated from T2 cells pulsed 
with YMNGTMSQV.  (A)  T2  cells (109) were preincubated with 0.5 
mM synthetic YMNGTMSQV for 12 h at 37~  before extraction and 
immunoafl~nity purification of HLA-A2.1 molecules. Pepddes were ex- 
tracted and material equivalent to 5 ￿  107 cells was analyzed as described 
in the legend to Fig. 2. (B) Synthetic YMNGTMSQV was added to an 
ahquot ofpeptide extract equivalent to that analyzed in A. (C) Synthetic 
YMDGTMSQV was added to an aliquot ofpeptide extract equivalent to 
that analyzed in A. 
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Nonetheless,  to  ensure  that this  conversion had not oc- 
curred during MHC  purification and peptide  extraction, 
the  antigen-processing mutant cell line  T2  (20,  21)  was 
pulsed with exogenous YMNGTMSQV,  and the  HLA- 
A2.1-associated  peptides  were  extracted.  Analysis  of this 
extract revealed a single peak in the mass range 1031-1032, 
corresponding  to  5.1  fmol/1.4  X  107  cells  (Fig.  4  A), 
which was  not  detected among peptides  extracted  from 
unpulsed T2  cells  (our unpublished  data).  Microcapillary 
HPLC demonstrated that this peptide coeluted with syn- 
thetic  YMNGTMSQV  (Fig.  4  B).  No  peak  of >0.05 
fiaaol/1.4  ￿  107 cells was observed at the elution position of 
synthetic  YMDGTMSQV  (compare  Fig.  4,  A  and  C). 
Thus, the conversion of asparagine  to aspartic  acid in the 
naturally processed peptide did not occur during the pep- 
tide extraction procedure, or while it was associated  with 
HLA-A2 at the cell surface. 
A  second  experiment  was  performed  to  establish 
whether spontaneous deamidation had occurred during the 
time that tyrosinase or tyrosinase-related peptides resided 
inside the  cell.  Whereas enzymatic deamidation of aspar- 
agine  residues  in  peptides  results  in  the  production  of 
a-linked aspartic  acid, spontaneous deamidation of aspar- 
agine-glycine  sequences  occurs  by  the  [3-aspartyl  shift 
mechanism, producing a mixture of or- and [3-hnked aspar- 
agine residues with an approximate ratio of 1 : 3  (32). Mi- 
crocapillary HPLC analysis demonstrated that a tyrosinase 
peptide containing [3-1inked aspartic acid [YM(I3-D)GTM- 
SQV]  could be  resolved from YMDGTMSQV  (Fig.  5). 
However, all of the naturally occurring tyrosinase peptide 
from NA8Mel+tyr cells  coeluted with YMDGTMSQV, 
and  none  was  detectable  at  the  elution  position  of the 
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Figure  5.  Ion chromatograms of peptides isolated from NA8Mel+tyr 
cells  analyzed  as  described for Fig.  2.  (A)  Ion chromatogram for m/z 
1,031-1,032 from NA8Mel+tyr material equivalent to 4 ￿  107 cells. (B) 
Ion  chromatogram  for  m/z  1,031-1,032  from  NA8Mel+tyr  material 
equivalent to 4  ￿  107 cells with synthetic YM(B-D)GTMSQV peptide 
added.  (D)  Ion chromatogram for m/z 1,031-1,032 from NA8Mel+tyr 
material equivalent to 4 ￿  107 cells with synthetic YMNGTMSQV pep- 
tide added. 
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13-1inked form (Fig. 5). Thus, the naturally occurring pep- 
tide  was  not  produced  by  a  spontaneous  deamidation 
mechanism. 
Discussion 
Our results establish that the natur~y occurring peptide 
corresponding to a tyrosinase epitope is distinct from that 
deduced from the  gene.  This modified peptide is recog- 
nized by tyrosinase-specific human CTL more effectively 
than the direct translation product, and is the only one of 
these  two peptides to be  presented by HLA-A2.1  mole- 
cules on the cell surface. Since the two peptides have a sim- 
ilar binding a~nity for HLA-A2.1, it would have been pre- 
dicted  that  both  would  be  found  among  the  naturally 
processed  peptides  with  this  MHC  molecule.  Conse- 
quently,  the  failure  to  detect  any significant amount  of 
YMNGTMSQV  while  the  quantity of YMDGTMSQV 
was  1,000  times  greater  than  background,  suggests  that 
spontaneous deamidation cannot account for the  genera- 
tion of this peptide epitope. The only explanation for the 
presence of the naturally processed species  is that it arises 
via an enzymatically posttranslafional modification that re- 
suits in the conversion of asparagine  to aspartic acid. 
Enzymatic deamidation of asparagine  to aspartate  could 
occur through the action of peptide:N-glycanase  (PNGase). 
This enzyme generates an aspartate through hydrulysis of the 
linkage  between  complex-type or high-mannose  glycans 
and asparagine  during degradation of N-linked glycopro- 
teins (33,  34).  A  less likely possibility is glycoasparaginase 
which has similar activity but acts preferentiaUy  on free gly- 
coasparagine  compared  to  peptide-bound  forms  (35-37). 
Tyrosinase  is  a  glycoprotein  that  contains  six  potential 
N-glycosylation sites (38, 39). One of these includes the as- 
paragine residue at position 371  which has been shown in 
the  present report  to  undergo posttranslational modifica- 
tion to aspartic  acid.  Given the strong probability that the 
N  residue in YMNGTMSQV is glycosylated (40), it seems 
most likely that this mechanism accounts for the presenta- 
tion  of YMDGTMSQV  in  association with  HLA-A2.1. 
Additionally, it should be pointed out that N-glycosylation 
of the asparagine  residue would protect it from nonenzy- 
matic deamidation. Furthermore, the attachment of a large 
carbohydrate side  chain would more than likely interfere 
with binding to HLA-A2.1, since this residue acts as a sec- 
ondary anchor  for  peptide  binding  (23).  In  either  case, 
these factors would result in the absence of the asparagine- 
containing form of this peptide on the cell surface. 
It is interesting to consider how this postulated mecha- 
nism for posttranslational conversion of this residue would 
fit into the pathway for processing and presentation of class 
I-associated peptides.  The conventional pathway involves 
the production of peptides from proteins expressed in the 
cytosol  and  subsequent  transport  into  the  endoplasmic 
reticulum (EtL) by the transporter associated  with antigen 
processing (TAP)  (41, 42).  Proteins that are membrane as- 
sociated  or  secreted  contain  signal  sequences  that  cause 
them to be  cotranslationally transferred into the ER from membrane-bound ribosomes. Such proteins would thus be 
protected  from  the  action  of cytoplasmic proteases.  Since 
peptide epitopes do arise from such proteins, it has been as- 
sumed that the proteolysis to generate these epitopes occurs 
after the proteins  have been aberrantly translated  on cyto- 
plasmic ribosomes  (1,  41).  However,  the  generation  of an 
aspartic  acid-containing  peptide  by the  action  of PNGase 
or glycosylasparaginase would necessitate synthesis of tyro- 
sinase on ElL-associated ribosomes for it to become N-gly- 
cosylated.  The sequence and location  of further processing 
steps is unknown.  PNGase is a soluble protein whose cellu- 
lar location  has  not  yet been  determined,  although  it  has 
virtually no activity at lysosomal pH (33, 34).  On the other 
hand,  glycoasparaginase is located exclusively in lysosomes 
(36); and N-glycosylated forms oftyrosinase have been ob- 
served  in  this  compartment  (40).  In  any  case,  tyrosinase 
would need to move from the ElL to the subcellular loca- 
tion  containing  one  of these enzymes to  allow generation 
of the  deglycosylated form of the peptide.  Given this  sce- 
nario,  it  also  remains  uncertain  whether  such  peptides 
would be dependent  upon the TAP complex for transport 
into the ElL. It is interesting that a peptide epitope derived 
from the HIV-1  envelope protein was shown to be gener- 
ated independently  of the  TAP complex,  whereas genera- 
tion of epitopes from the transmembrane fusion protein of 
measles virus were dependent  upon TAP  (43,  44).  Further 
investigation  into  the  N-glycosylation/N-deglycosylation 
and  the  catabolism  of tyrosine  should  reveal the  processes 
involved in formation of this naturally occurring posttrans- 
lationally modified tyrosinase epitope and their significance 
to  class  I  antigen  presentation.  Such  a  mechanism  may be 
generally  applicable  to  the  presentation  of both  glycosy- 
lated and nonglycosylated proteins from membrane-bound 
and -secreted proteins. 
The  identification  of the  naturally  occurring  tyrosinase 
epitope  YMDGTMSQV  involved  two  alternative  strate- 
gies. These complementary techniques  reveal that this nat- 
urally occurring peptide undergoes a posttranslational mod- 
ification that is relevant to the identification  and prediction 
of other peptide  antigens.  The results presented  here indi- 
cate that  the peptide  structures  presented  by MHC  mole- 
cules may not be directly predictable  from a DNA  coding 
sequence.  Other peptides associated with class  II molecules 
have been previously shown to be posttranslationally mod- 
ified  by  the  attachment  of carbohydrate  side  chains  (45, 
46),  and  the  extent  of carbohydrate  attachment  has  been 
shown to affect T  cell recognition ofpeptide structures  (46, 
47).  However,  a posttranslational  modification  that results 
in an alteration  in the primary amino acid sequence  of the 
peptide  has not been previously reported.  Our results  also 
suggest  that  changes  in  the  regulation  of posttranslational 
modification in different cells could lead to the generation 
of new  antigens.  Such  antigens  could  be  relevant  both  to 
autoimmunity and to tumor rejection. 
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